BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsClinical readout

Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update expected in the second half of 2026 Comprehensive Danon disease

Related news

RCKTRocket Pharmaceuticals2026-09-15 11:00 EST

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

ARWRArrowhead Pharmaceuticals2026-09-15 11:30 EST

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ARWRArrowhead Pharmaceuticals2026-08-30 15:30 EST

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

IRONDisc Medicine2026-09-09 23:25 EST

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

MNPRMonopar2026-06-26 20:05 EST

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

VYGRVoyager Therapeutics2026-07-13 12:01 EST

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

PHVSPharvaris2026-09-08 10:50 EST

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

AGIOAgios Pharmaceuticals, Inc.2026-07-21 11:00 EST

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

View all latest news

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

RCKTRocket Pharmaceuticals2026-09-15 11:00 EST

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

RCKTRocket Pharmaceuticals2026-06-12 11:00 EST

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Stock data

Close
3.37 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States